Evenly matched
251 companies value 203 bn revenue 1.5 bn margin -342.7% free cash flow -19 bn avg. score 0.4
RVMD holds 19.2% of the group's value, 1.6x the runner-up
| Rank | Ticker | Company | Share | Value | Revenue | Margin | FCF | 5 years | FCF/px | Yield | What it does · why it is here |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | RVMD | Revolution Medicines, Inc. United States · score 0.0 | 19% | 39 bn | 0.0 bn | — | -1.2 bn | -3.2% | — | Precision oncology for RAS-addicted cancers · California | |
| 2 | ROIV | Roivant Sciences Ltd. United Kingdom · score 0.0 | 12% | 25 bn | 0.0 bn | -35x | -0.8 bn | -3.3% | — | Biopharma accelerating drug development · United Kingdom — revenue of $8m | |
| 3 | PRAX | Praxis Precision Medicines, Inc. United States · score 0.0 | 4% | 7.3 bn | 0.0 bn | — | -0.3 bn | -4.2% | — | Precision neuroscience biopharma for CNS disorders · Massachusetts | |
| 4 | ABVX | Abivax S.A. France · score 0.0 | 3% | 6.9 bn | 0.0 bn | -80x | -0.2 bn | -3.2% | — | Therapies for chronic inflammatory diseases, from France · France — revenue of $6m | |
| 5 | BLTE | BELITE BIO, INC United States · score 0.3 | 3% | 5.8 bn | — | — | -0.0 bn | -0.6% | — | Therapies for retinal diseases · California | |
| 6 | COGT | Cogent Biosciences, Inc. United States · score 0.0 | 3% | 5.2 bn | — | — | -0.3 bn | -5.9% | — | Clinical-stage biotech in precision therapies · Massachusetts | |
| 7 | MANE | Veradermics, Inc United States · score 0.7 | 3% | 5.1 bn | — | — | -0.1 bn | -1.5% | — | Clinical-stage biopharma for dermatology and aesthetics · Connecticut | |
| 8 | RGC | Regencell Bioscience Holdings Ltd Hong Kong · score 0.2 | 3% | 5.0 bn | — | — | -0.0 bn | -0.2% | — | Traditional Chinese medicine bioscience for ADHD and autism · Hong Kong | |
| 9 | ERAS | Erasca, Inc. United States · score 0.0 | 2% | 4.8 bn | — | — | -0.1 bn | -2.1% | — | Clinical-stage precision oncology for RAS/MAPK pathway cancers · California | |
| 10 | DFTX | Definium Therapeutics, Inc. United States · score 0.2 | 2% | 4.4 bn | — | — | -0.2 bn | -3.8% | — | Clinical-stage biopharma for brain health disorders · New York | |
| 11 | EWTX | Edgewise Therapeutics, Inc. United States · score 0.0 | 2% | 4.1 bn | — | — | -0.2 bn | -3.9% | — | Sarcomere modulators for muscle diseases · Colorado | |
| 12 | RLAY | Relay Therapeutics, Inc. United States · score 0.0 | 2% | 3.7 bn | 0.0 bn | -28x | -0.2 bn | -5.7% | — | Small-molecule precision medicine for cancer · Massachusetts — revenue of $10m | |
| 13 | AMLX | Amylyx Pharmaceuticals, Inc. United States · score 0.1 | 2% | 3.4 bn | 0.0 bn | — | -0.1 bn | -3.7% | — | Clinical-stage pharma in therapies for unmet needs · Massachusetts | |
| 14 | XENE | Xenon Pharmaceuticals Inc. Canada · score 0.0 | 2% | 3.4 bn | 0.0 bn | — | -0.3 bn | -10.0% | — | Neuroscience biopharma · Canada | |
| 15 | PBLS | Parabilis Medicines, Inc. United States · score 5.3 | 2% | 3.1 bn | — | — | — | — | — | — | Medicines for protein targets considered undruggable · Massachusetts |
| 16 | IRON | Disc Medicine, Inc. United States · score 0.0 | 2% | 3.0 bn | — | — | -0.2 bn | -6.5% | — | Clinical-stage biopharma in serious blood diseases · Massachusetts | |
| 17 | VKTX | Viking Therapeutics, Inc. United States · score 0.0 | 1% | 2.9 bn | 0.0 bn | — | -0.4 bn | -14.3% | — | Therapies for metabolic and endocrine disorders · California | |
| 18 | ELVN | Enliven Therapeutics, Inc. United States · score 0.2 | 1% | 2.8 bn | — | — | -0.1 bn | -2.4% | — | Clinical-stage biopharma of small molecules · California | |
| 19 | NRIX | Nurix Therapeutics, Inc. United States · score 6.5 | 1% | 2.7 bn | 0.7 bn | 42.0% | 0.4 bn | 13.6% | — | Clinical-stage biopharma in targeted protein degradation · California — revenue of $702m | |
| 20 | MBX | MBX Biosciences, Inc. United States · score 0.0 | 1% | 2.5 bn | — | — | -0.1 bn | -3.4% | — | Clinical-stage biopharma in peptides for endocrine disorders · Indiana | |
| 21 | NAMS | NewAmsterdam Pharma Co N.V. Netherlands · score 0.0 | 1% | 2.4 bn | 0.0 bn | -36x | -0.1 bn | -5.9% | — | Late-stage biopharma in cardiometabolic diseases · Netherlands — revenue of $7m | |
| 22 | SLS | SELLAS Life Sciences Group, Inc. United States · score 0.2 | 1% | 2.1 bn | — | — | -0.0 bn | -1.3% | — | Clinical-stage biopharma of cancer therapies · New York | |
| 23 | IMNM | Immunome Inc. United States · score 0.0 | 1% | 1.9 bn | 0.0 bn | — | -0.2 bn | -11.5% | — | Biotech developing targeted oncology therapies · Washington | |
| 24 | PHVS | Pharvaris N.V. Netherlands · score 0.0 | 1% | 1.9 bn | — | — | -0.2 bn | -9.0% | — | Oral medicines for hereditary angioedema, from the Netherlands · Netherlands | |
| 25 | MLYS | Mineralys Therapeutics, Inc. United States · score 0.0 | 1% | 1.8 bn | — | — | -0.1 bn | -7.5% | — | Biopharma for aldosterone-driven diseases · Pennsylvania | |
| 26 | PVLA | PALVELLA THERAPEUTICS, INC. United States · score 0.4 | 1% | 1.8 bn | — | — | -0.0 bn | -2.1% | — | Drugs for rare cutaneous vascular malformations · Pennsylvania | |
| 27 | BRVE | Braveheart Bio, Inc. United States · score 4.0 | 1% | 1.7 bn | — | — | — | — | — | — | Cardiovascular biotech · California |
| 28 | BHVN | Biohaven Ltd. United States · score 0.0 | 1% | 1.7 bn | — | — | -0.5 bn | -29.9% | — | Biopharma in immunology, neuroscience and oncology · Connecticut | |
| 29 | TRVI | Trevi Therapeutics, Inc. United States · score 0.1 | 1% | 1.7 bn | — | — | -0.1 bn | -3.1% | — | Clinical-stage biopharma of a treatment for chronic cough · Connecticut | |
| 30 | MAZE | Maze Therapeutics, Inc. United States · score 0.1 | 1% | 1.6 bn | 0.0 bn | -53x | -0.1 bn | -6.5% | — | Clinical-stage biopharma of precision medicine for kidney and metabolic diseases · California — revenue of $2m | |
| 31 | GPCR | Structure Therapeutics Inc. United States · score 0.0 | 1% | 1.6 bn | — | — | -0.2 bn | -14.3% | — | Clinical-stage biopharma of oral molecules for chronic diseases · California | |
| 32 | CMPS | COMPASS Pathways plc United Kingdom · score 0.0 | 1% | 1.5 bn | — | — | -0.2 bn | -10.5% | — | Evidence-based innovation biotech for mental health · United Kingdom | |
| 33 | KLRA | Kailera Therapeutics, Inc. United States · score 5.0 | 1% | 1.5 bn | — | — | — | — | — | — | Obesity drugs licensed from Hengrui · Massachusetts |
| 34 | RAPP | Rapport Therapeutics, Inc. United States · score 0.0 | 1% | 1.4 bn | 0.0 bn | -685.8% | -0.1 bn | -7.1% | — | Precision molecules for neurological and psychiatric disorders · Massachusetts — revenue of $20m | |
| 35 | TYRA | Tyra Biosciences, Inc. United States · score 0.0 | 1% | 1.3 bn | — | — | -0.1 bn | -8.3% | — | FGFR-targeted precision medicine in oncology · California | |
| 36 | ORIC | Oric Pharmaceuticals, Inc. United States · score 0.0 | 1% | 1.3 bn | — | — | -0.1 bn | -8.5% | — | Clinical-stage biopharma in cancer resistance · California | |
| 37 | LBRX | LB PHARMACEUTICALS INC United States · score 0.4 | 1% | 1.3 bn | — | — | -0.1 bn | -6.6% | — | Therapies for schizophrenia and bipolar depression · New York | |
| 38 | KARD | Kardigan, Inc. United States · score 5.0 | 1% | 1.2 bn | — | — | — | — | — | — | Cardiovascular medicines backed by digital patient data · California |
| 39 | GHRS | GH Research PLC Ireland · score 0.4 | 1% | 1.1 bn | — | — | -0.1 bn | -4.6% | — | Clinical-stage biopharma of a depression treatment · Ireland | |
| 40 | NBTX | Nanobiotix S.A. France · score 0.0 | 1% | 1.0 bn | 0.0 bn | -42.6% | -0.0 bn | -3.9% | — | Nanoparticle-enhanced radiotherapy, from France · France — revenue of $13m | |
| 41 | AVLN | Avalyn Pharma Inc. United States · score 5.2 | 1% | 1.0 bn | — | — | — | — | — | — | Inhaled medicines for pulmonary fibrosis · Massachusetts |
| 42 | SPTX | Seaport Therapeutics, Inc. United States · score 5.0 | 1% | 1.0 bn | — | — | — | — | — | — | Neuropsychiatry medicines · Massachusetts |
| 43 | GLUE | Monte Rosa Therapeutics, Inc. United States · score 0.0 | 0% | 0.9 bn | 0.0 bn | -560.8% | -0.0 bn | -3.5% | — | Clinical-stage biotech of molecular glue degraders · Massachusetts — revenue of $29m | |
| 44 | LTGO | Latigo Biotherapeutics, Inc. United States · score 4.0 | 1% | 0.9 bn | — | — | — | — | — | — | Clinical-stage non-opioid pain medicines · California |
| 45 | ANRO | Alto Neuroscience, Inc. United States · score 0.0 | 0% | 0.9 bn | — | — | -0.1 bn | -7.7% | — | Clinical-stage precision psychiatry biopharma · California | |
| 46 | AVBP | ArriVent BioPharma, Inc. United States · score 0.0 | 0% | 0.9 bn | — | — | -0.1 bn | -16.7% | — | Clinical-stage biopharma in oncology drugs · Pennsylvania | |
| 47 | AKTS | Aktis Oncology, Inc. United States · score 0.0 | 0% | 0.8 bn | 0.0 bn | -727.0% | -0.1 bn | — | -10.1% | — | Targeted radiopharmaceuticals for solid tumors · Massachusetts — revenue of $10m |
| 48 | ALMS | ALUMIS INC. United States · score 0.0 | 0% | 0.8 bn | 0.0 bn | -59x | -0.3 bn | -42.9% | — | Clinical-stage biopharma in TYK2 inhibitors · California — revenue of $7m | |
| 49 | SGP | SpyGlass Pharma, Inc. United States · score 0.4 | 0% | 0.8 bn | — | — | -0.1 bn | -6.0% | — | Late-stage biopharma of sustained-release eye treatments · California | |
| 50 | CRVS | Corvus Pharmaceuticals, Inc. United States · score 0.0 | 0% | 0.8 bn | — | — | -0.1 bn | -5.6% | — | Clinical-stage biopharma of immune system proteins · California | |
| 51 | HELP | CYBIN INC. Canada · score 0.0 | 0% | 0.8 bn | — | — | -0.1 bn | -17.1% | — | Psychedelics for mental health, from Canada · Canada | |
| 52 | LXRX | LEXICON PHARMACEUTICALS, INC. United States · score 0.0 | 0% | 0.7 bn | 0.0 bn | -147.4% | -0.1 bn | -9.4% | — | Biopharma developing transformative medicines · Texas — revenue of $41m | |
| 53 | ANL | Adlai Nortye Group Ltd. Singapore · score 0.0 | 0% | 0.7 bn | 0.0 bn | -710.6% | -0.0 bn | -5.0% | — | Clinical-stage oncology, from China · Singapore — revenue of $5m | |
| 54 | IVA | Inventiva S.A. France · score 0.0 | 0% | 0.7 bn | 0.0 bn | -5051x | -0.1 bn | -15.4% | — | Medicines for liver diseases, from France · France | |
| 55 | DSGN | Design Therapeutics, Inc. United States · score 0.0 | 0% | 0.7 bn | 0.0 bn | — | -0.1 bn | -8.3% | — | GeneTAC molecules for genetic diseases · California | |
| 56 | ACHV | ACHIEVE LIFE SCIENCES, INC. United States · score 0.0 | 0% | 0.7 bn | — | — | -0.1 bn | -6.9% | — | Medicines for nicotine dependence · Washington | |
| 57 | SGMT | Sagimet Biosciences Inc. United States · score 0.0 | 0% | 0.6 bn | — | — | -0.0 bn | -6.7% | — | Clinical-stage biopharma in FASN inhibitors · California | |
| 58 | OLMA | Olema Pharmaceuticals, Inc. United States · score 0.0 | 0% | 0.6 bn | — | — | -0.2 bn | -26.5% | — | Clinical-stage biopharma in breast cancer therapies · California | |
| 59 | NVCT | Nuvectis Pharma, Inc. United States · score 0.0 | 0% | 0.6 bn | — | — | -0.0 bn | -3.2% | — | Clinical-stage biopharma in precision oncology medicine · New Jersey | |
| 60 | DBVT | DBV Technologies S.A. France · score 0.0 | 0% | 0.5 bn | 0.0 bn | -35x | -0.2 bn | -32.1% | — | Late-stage immunotherapy biopharma with the Viaskin platform · France — revenue of $5m | |
| 61 | ACRS | Aclaris Therapeutics, Inc. United States · score 0.0 | 0% | 0.5 bn | 0.0 bn | -921.5% | -0.1 bn | -12.1% | — | Immuno-inflammatory drugs in development and partnerships · Pennsylvania — revenue of $8m | |
| 62 | ENTX | Entera Bio Ltd. Israel · score 0.2 | 0% | 0.5 bn | 0.0 bn | — | -0.0 bn | -2.2% | — | Clinical-stage oral formulations of peptides and proteins · Israel | |
| 63 | MNPR | Monopar Therapeutics United States · score 0.3 | 0% | 0.5 bn | 0.0 bn | — | -0.0 bn | -2.5% | — | Clinical-stage cancer medicines · Illinois | |
| 64 | DRUG | BRIGHT MINDS BIOSCIENCES INC. United States · score 0.4 | 0% | 0.5 bn | — | — | -0.0 bn | -1.2% | — | Next-generation psychedelics for neuropsychiatric disorders · Illinois | |
| 65 | FTH | Faeth Therapeutics, Inc. United States · score 0.0 | 0% | 0.5 bn | — | — | -0.0 bn | -6.7% | — | Clinical-stage biotech inhibiting oncogenic pathways · Texas | |
| 66 | BLSM | BlossomHill Therapeutics, Inc. United States · score 4.0 | 0% | 0.5 bn | — | — | — | — | — | — | Small-molecule drugs for EGFR-mutant lung cancer and acute myeloid leukemia, in clinical stage · California |
| 67 | CCCC | C4 Therapeutics, Inc. United States · score 0.0 | 0% | 0.4 bn | 0.0 bn | -289.4% | -0.1 bn | -24.0% | — | Clinical-stage biopharma of targeted protein degradation · Massachusetts — revenue of $35m | |
| 68 | ALT | Altimmune, Inc. United States · score 0.0 | 0% | 0.4 bn | 0.0 bn | -2238x | -0.1 bn | -17.6% | — | Drugs for serious liver diseases · Maryland | |
| 69 | OCS | Oculis Holding AG Switzerland · score 0.0 | 0% | 0.4 bn | 0.0 bn | -68x | -0.1 bn | -18.8% | — | Ophthalmic therapies, from Switzerland · Switzerland — revenue of $1m | |
| 70 | OVID | Ovid Therapeutics Inc. United States · score 0.0 | 0% | 0.4 bn | 0.0 bn | -22x | -0.1 bn | -12.9% | — | Biopharma in small molecules for brain disorders · New York — revenue of $2m | |
| 71 | GALT | GALECTIN THERAPEUTICS INC United States · score 0.0 | 0% | 0.4 bn | — | — | -0.0 bn | -4.5% | — | Clinical-stage biopharma in fibrosis and cancer · Georgia | |
| 72 | AVIR | Atea Pharmaceuticals, Inc. United States · score 0.0 | 0% | 0.4 bn | — | — | -0.1 bn | -43.2% | — | Late-stage biopharma in oral antivirals · Massachusetts | |
| 73 | PRLD | Prelude Therapeutics Inc United States · score 0.0 | 0% | 0.3 bn | 0.0 bn | -269.7% | -0.0 bn | -12.3% | — | Clinical-stage precision oncology · Delaware — revenue of $22m | |
| 74 | XFOR | X4 Pharmaceuticals, Inc United States · score 0.0 | 0% | 0.3 bn | 0.0 bn | -10x | -0.1 bn | -30.7% | — | Biopharma in rare blood disorders · Massachusetts — revenue of $9m | |
| 75 | FULC | Fulcrum Therapeutics, Inc. United States · score 0.0 | 0% | 0.3 bn | 0.0 bn | — | -0.1 bn | -23.4% | — | Clinical-stage biopharma in rare genetic diseases · Massachusetts | |
| 76 | RLMD | RELMADA THERAPEUTICS, INC. United States · score 0.0 | 0% | 0.3 bn | — | — | -0.1 bn | -13.6% | — | Clinical-stage biotech · Florida | |
| 77 | TTRX | Turn Therapeutics Inc. United States · score 0.2 | 0% | 0.3 bn | — | — | 0.0 bn | -1.4% | — | Clinical-stage topical antimicrobials · California | |
| 78 | CTNM | Contineum Therapeutics, Inc. United States · score 0.0 | 0% | 0.3 bn | — | — | -0.1 bn | -19.1% | — | Clinical-stage biopharma in neuroimmune diseases · California | |
| 79 | ACIU | AC Immune SA Switzerland · score 0.0 | 0% | 0.2 bn | 0.0 bn | -246.5% | -0.1 bn | -25.0% | — | Therapies for Alzheimer's and neurodegenerative diseases, from Switzerland · Switzerland — revenue of $21m | |
| 80 | ACOG | Alpha Cognition Inc. United States · score 0.0 | 0% | 0.2 bn | 0.0 bn | -137.7% | -0.0 bn | -16.8% | — | Biopharma for neurodegenerative diseases such as Alzheimer's · Texas — revenue of $15m | |
| 81 | BIOA | BioAge Labs, Inc. United States · score 0.0 | 0% | 0.2 bn | 0.0 bn | -912.3% | -0.1 bn | -38.5% | — | Clinical-stage biopharma in metabolic diseases of aging · California — revenue of $10m | |
| 82 | EVMN | Evommune, Inc. United States · score 0.0 | 0% | 0.2 bn | 0.0 bn | -946.7% | -0.1 bn | -39.0% | — | Therapies for chronic inflammatory diseases · California — revenue of $10m | |
| 83 | PALI | PALISADE BIO, INC. United States · score 0.0 | 0% | 0.2 bn | 0.0 bn | — | -0.0 bn | -7.8% | — | Clinical-stage biopharma of oral PDE4 inhibitors · California | |
| 84 | IKT | Inhibikase Therapeutics, Inc. United States · score 0.0 | 0% | 0.2 bn | 0.0 bn | — | -0.0 bn | -18.6% | — | Clinical-stage pharma in pulmonary arterial hypertension · Delaware | |
| 85 | ZNTL | Zentalis Pharmaceuticals, Inc. United States · score 0.0 | 0% | 0.2 bn | 0.0 bn | — | -0.1 bn | -57.8% | — | Clinical-stage biopharma with a WEE1 inhibitor · California | |
| 86 | IFRX | InflaRx N.V. Germany · score 0.0 | 0% | 0.2 bn | 0.0 bn | -1551x | -0.0 bn | -18.5% | — | Complement system inhibitors (C5a/C5aR) for inflammatory and autoimmune diseases, in clinical development · Germany | |
| 87 | SLGL | Sol-Gel Technologies Ltd. Israel · score 0.1 | 0% | 0.2 bn | 0.0 bn | -910.1% | -0.0 bn | -4.0% | — | Topical dermatology, from Israel · Israel — revenue of $2m | |
| 88 | ORMP | ORAMED PHARMACEUTICALS INC. United States · score 2.7 | 0% | 0.2 bn | 0.0 bn | 87x | -0.0 bn | -3.1% | — | Oral delivery of therapeutic proteins, from Israel · New York — revenue of $2m | |
| 89 | CATX | Perspective Therapeutics, Inc. United States · score 0.0 | 0% | 0.2 bn | — | — | -0.1 bn | -48.5% | — | Radiopharmaceuticals for cancer treatment · Washington | |
| 90 | IMRX | Immuneering Corp United States · score 0.0 | 0% | 0.2 bn | — | — | -0.1 bn | -24.1% | — | Late clinical-stage oncology · Massachusetts | |
| 91 | VOGX | Vogenx, Inc. United States · score 4.0 | 0% | 0.2 bn | — | — | — | — | — | — | Oral drug for post-bariatric surgery hypoglycemia and gastroparesis, in clinical development · North Carolina |
| 92 | BBOT | BridgeBio Oncology Therapeutics, Inc. United States · score 0.0 | 0% | 0.2 bn | — | — | -0.1 bn | -66.3% | — | Oncology targeting RAS and PI3Kα mutations · California | |
| 93 | SION | Sionna Therapeutics, Inc. United States · score 0.0 | 0% | 0.2 bn | — | — | -0.1 bn | -42.0% | — | Clinical-stage biopharma in cystic fibrosis · Massachusetts | |
| 94 | SPRO | Spero Therapeutics, Inc. United States · score 7.4 | 0% | 0.1 bn | 0.1 bn | 15.7% | 0.0 bn | 30.0% | — | Clinical-stage biopharma in rare diseases · Massachusetts — revenue of $47m | |
| 95 | FHTX | Foghorn Therapeutics Inc. United States · score 0.0 | 0% | 0.1 bn | 0.0 bn | -175.8% | -0.1 bn | -75.9% | — | Clinical-stage biotech in chromatin regulation · Massachusetts — revenue of $37m | |
| 96 | VTVT | vTv Therapeutics Inc. United States · score 0.0 | 0% | 0.1 bn | 0.0 bn | -12.9% | -0.0 bn | -15.7% | — | Late-stage biopharma in metabolic and inflammatory diseases · North Carolina — revenue of $37m | |
| 97 | CPIX | CUMBERLAND PHARMACEUTICALS INC United States · score 2.5 | 0% | 0.1 bn | 0.0 bn | -27.4% | 0.0 bn | 0.7% | — | Specialty pharma of branded prescription drugs · Tennessee — revenue of $40m | |
| 98 | PTHS | Pelthos Therapeutics Inc. United States · score 0.0 | 0% | 0.1 bn | 0.0 bn | -199.5% | -0.0 bn | -54.9% | — | Biopharma developing innovative therapeutics · North Carolina — revenue of $43m | |
| 99 | TNXP | Tonix Pharmaceuticals Holding Corp. United States · score 0.0 | 0% | 0.1 bn | 0.0 bn | -548.6% | -0.2 bn | -160.8% | — | Drug for fibromyalgia and other nervous system conditions · New Jersey — revenue of $29m | |
| 100 | VRCA | Verrica Pharmaceuticals Inc. United States · score 0.0 | 0% | 0.1 bn | 0.0 bn | -102.8% | -0.0 bn | -22.6% | — | Therapies for skin diseases, including skin cancer · Pennsylvania — revenue of $30m | |
| 101 | LENZ | LENZ Therapeutics, Inc. United States · score 0.0 | 0% | 0.1 bn | 0.0 bn | -586.7% | -0.1 bn | -110.3% | — | Commercial pharma of vision therapies · California — revenue of $21m | |
| 102 | SPRB | SPRUCE BIOSCIENCES, INC. United States · score 0.0 | 0% | 0.1 bn | 0.0 bn | — | -0.0 bn | -36.7% | — | Biopharma in therapies for neurological disorders · California | |
| 103 | NRXP | NRX Pharmaceuticals, Inc. United States · score 0.0 | 0% | 0.1 bn | 0.0 bn | -691.8% | -0.0 bn | -17.4% | — | Interventional psychiatry and neuroplastic therapies · Delaware — revenue of $3m | |
| 104 | BDTX | Black Diamond Therapeutics, Inc. United States · score 0.0 | 0% | 0.1 bn | 0.0 bn | — | -0.0 bn | -31.6% | — | Clinical-stage oncology of therapies for oncogenic mutations · Massachusetts | |
| 105 | MBRX | Moleculin Biotech, Inc. United States · score 0.0 | 0% | 0.1 bn | 0.0 bn | — | -0.0 bn | -24.7% | — | Biopharma of a next-generation anthracycline · Texas | |
| 106 | VANI | Vivani Medical, Inc. United States · score 0.0 | 0% | 0.1 bn | 0.0 bn | — | -0.0 bn | -26.2% | — | Clinical-stage biopharma of sustained-release implants · California | |
| 107 | RANI | Rani Therapeutics Holdings, Inc. United States · score 0.0 | 0% | 0.1 bn | 0.0 bn | -618.0% | -0.0 bn | -22.4% | — | Clinical-stage biotech of oral delivery of biologics · California — revenue of $5m | |
| 108 | AARD | Aardvark Therapeutics, Inc. United States · score 0.0 | 0% | 0.1 bn | 0.0 bn | — | -0.1 bn | -84.9% | — | Molecules for metabolic diseases and obesity · California | |
| 109 | NTRB | NutriBand Inc. United States · score 0.0 | 0% | 0.1 bn | 0.0 bn | -430.3% | 0.0 bn | -5.0% | — | Transdermal patches for drug delivery · Florida — revenue of $2m | |
| 110 | CRDF | Cardiff Oncology, Inc. United States · score 0.0 | 0% | 0.1 bn | 0.0 bn | -79x | -0.0 bn | -59.1% | — | Clinical-stage biotech in PLK1 inhibition for oncology · California | |
| 111 | MNOV | MEDICINOVA INC United States · score 0.0 | 0% | 0.1 bn | 0.0 bn | -12x | -0.0 bn | -13.2% | — | Biopharma of therapies for serious diseases · California | |
| 112 | RFL | Rafael Holdings, Inc. United States · score 0.0 | 0% | 0.1 bn | 0.0 bn | -21x | -0.0 bn | -47.7% | — | Biotech and stakes in pharmaceutical companies · New Jersey | |
| 113 | TENX | TENAX THERAPEUTICS, INC. United States · score 0.0 | 0% | 0.1 bn | 0.0 bn | — | -0.1 bn | -80.9% | — | Clinical-stage cardiovascular drugs · North Carolina | |
| 114 | TLPH | TALPHERA, INC. United States · score 0.0 | 0% | 0.1 bn | 0.0 bn | -15076x | -0.0 bn | -21.9% | — | Specialty pharma for medically supervised use · California | |
| 115 | PLRX | PLIANT THERAPEUTICS, INC. United States · score 0.0 | 0% | 0.1 bn | 0.0 bn | — | -0.1 bn | -127.3% | — | Integrin-based therapies for fibrosis · California | |
| 116 | ELOX | Eloxx Pharmaceuticals, Inc. United States · score 0.0 | 0% | 0.1 bn | 0.0 bn | — | -0.0 bn | -31.7% | — | Premature stop codon readthrough molecules · Massachusetts | |
| 117 | MENS | Jyong Biotech Ltd. Taiwan · score 0.0 | 0% | 0.1 bn | — | — | 0.0 bn | -2.1% | — | Botanical medicines, from Taiwan, since 2002 · Taiwan | |
| 118 | ANTX | AN2 Therapeutics, Inc. United States · score 0.0 | 0% | 0.1 bn | — | — | -0.0 bn | -24.1% | — | Clinical-stage biopharma in boron chemistry · California | |
| 119 | AVXL | ANAVEX LIFE SCIENCES CORP. United States · score 0.0 | 0% | 0.1 bn | — | — | -0.0 bn | -25.3% | — | Medicines for Alzheimer's, Parkinson's and rare diseases · New York | |
| 120 | NERV | Minerva Neurosciences, Inc. United States · score 0.6 | 0% | 0.1 bn | — | — | -0.0 bn | -23.6% | — | Medicines for central nervous system diseases · Massachusetts | |
| 121 | UNCY | Unicycive Therapeutics, Inc. United States · score 0.0 | 0% | 0.1 bn | — | — | -0.0 bn | -28.5% | — | Clinical-stage biotech in kidney disease · California | |
| 122 | PLYX | Polaryx Therapeutics, Inc. United States · score 0.5 | 0% | 0.1 bn | — | — | -0.0 bn | -6.1% | — | Clinical-stage biotech in pediatric lysosomal diseases · New Jersey | |
| 123 | IMUX | IMMUNIC, INC. United States · score 0.0 | 0% | 0.1 bn | — | — | -0.1 bn | -92.3% | — | Late-stage biotech of oral therapies for neurological and gastrointestinal diseases · United States | |
| 124 | PMVP | PMV Pharmaceuticals, Inc. United States · score 0.0 | 0% | 0.1 bn | — | — | -0.1 bn | -75.2% | — | Precision oncology targeting the p53 protein · New Jersey | |
| 125 | OKUR | OnKure Therapeutics, Inc. United States · score 0.0 | 0% | 0.1 bn | — | — | -0.1 bn | -52.5% | — | Clinical-stage biopharma in precision oncology medicine · Colorado | |
| 126 | NMRA | Neumora Therapeutics, Inc. United States · score 0.0 | 0% | 0.1 bn | — | — | -0.2 bn | -204.4% | — | Clinical-stage biopharma of brain-penetrant chemistry · Massachusetts | |
| 127 | MIST | Milestone Pharmaceuticals Inc. Canada · score 0.0 | 0% | 0.1 bn | — | — | -0.1 bn | -70.8% | — | Pharma of the CARDAMYST nasal spray · Canada | |
| 128 | OKYO | OKYO Pharma Ltd United Kingdom · score 0.0 | 0% | 0.1 bn | — | — | -0.0 bn | -8.1% | — | Ophthalmic therapies for neuropathic eye pain · United Kingdom | |
| 129 | ACRV | Acrivon Therapeutics, Inc. United States · score 0.0 | 0% | 0.1 bn | — | — | -0.1 bn | -88.6% | — | Clinical-stage biopharma in precision proteomics · Massachusetts | |
| 130 | TELO | Telomir Pharmaceuticals, Inc. United States · score 0.0 | 0% | 0.1 bn | — | — | 0.0 bn | -6.9% | — | Preclinical biotech of anti-aging molecules · Florida | |
| 131 | CGTX | COGNITION THERAPEUTICS INC United States · score 0.0 | 0% | 0.1 bn | — | — | -0.0 bn | -25.6% | — | Clinical-stage biopharma for degenerative CNS diseases · New York | |
| 132 | MAIA | MAIA Biotechnology, Inc. United States · score 0.0 | 0% | 0.1 bn | — | — | -0.0 bn | -34.7% | — | Clinical-stage biopharma in cancer immunotherapies · Illinois | |
| 133 | CING | Cingulate Inc. United States · score 0.0 | 0% | 0.1 bn | — | — | -0.0 bn | -33.0% | — | Pharma developing timed-release drug delivery · Kansas | |
| 134 | BMEA | Biomea Fusion, Inc. United States · score 0.0 | 0% | 0.1 bn | — | — | -0.1 bn | -78.0% | — | Clinical-stage biopharma in diabetes and obesity · California | |
| 135 | GANX | Gain Therapeutics, Inc. United States · score 0.0 | 0% | 0.1 bn | — | — | -0.0 bn | -34.7% | — | Biotech in small molecules for CNS and lysosomal diseases · Maryland | |
| 136 | BOLD | Boundless Bio, Inc. United States · score 0.0 | 0% | 0.1 bn | — | — | -0.1 bn | -108.1% | — | Oncology targeting extrachromosomal DNA · California | |
| 137 | BFRI | Biofrontera Inc. United States · score 0.0 | 0% | 0.0 bn | 0.1 bn | -13.8% | -0.0 bn | -66.1% | — | Biopharma in photodynamic therapy for dermatology · Massachusetts — revenue of $46m | |
| 138 | SCLX | Scilex Holding Co United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | -15x | -0.0 bn | -81.7% | — | Non-opioid pain management products · California — revenue of $32m | |
| 139 | SCYX | SCYNEXIS INC United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | -53.3% | -0.0 bn | -36.6% | — | Antifungal for resistant infections · New Jersey — revenue of $19m | |
| 140 | ATHE | ALTERITY THERAPEUTICS LTD Australia · score 0.0 | 0% | 0.0 bn | 0.0 bn | -289.3% | -0.0 bn | -35.8% | — | Oral drug for multiple system atrophy and other Parkinsonian disorders, in clinical development · Australia — revenue of $6m | |
| 141 | CTXR | Citius Pharmaceuticals, Inc. United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | -818.7% | -0.0 bn | -298.0% | — | Biopharma in critical care and oncology products · New Jersey — revenue of $7m | |
| 142 | PTN | PALATIN TECHNOLOGIES INC United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | -94.9% | -0.0 bn | -127.0% | — | Biopharma of melanocortin system modulators · New Jersey — revenue of $9m | |
| 143 | RNTX | Rein Therapeutics, Inc. United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | — | -0.0 bn | -39.6% | — | Therapies for pulmonary fibrosis and rare diseases · Texas | |
| 144 | CLNN | Clene Inc. United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | -201x | -0.0 bn | -37.7% | — | Clinical-stage pharma in clean-surface nanotechnology · Utah | |
| 145 | SER | Serina Therapeutics, Inc. United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | — | -0.0 bn | -50.6% | — | Clinical-stage biotech in neurological diseases · Alabama | |
| 146 | ATNM | Actinium Pharmaceuticals, Inc. United States · score 1.1 | 0% | 0.0 bn | 0.0 bn | 126x | -0.0 bn | -54.9% | — | Radiopharmaceuticals for solid tumors and blood cancers · New York | |
| 147 | ANVS | Annovis Bio, Inc. United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | — | -0.0 bn | -106.0% | — | Late-stage pharma in Alzheimer's and Parkinson's · Pennsylvania | |
| 148 | EYPT | EyePoint, Inc. United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | -110x | -0.3 bn | -715.8% | — | Clinical-stage biopharma in serious retinal diseases · Massachusetts — revenue of $3m | |
| 149 | CRVO | CervoMed Inc. United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | -92x | -0.0 bn | -80.2% | — | Clinical-stage biotech in brain disorders of aging · Massachusetts | |
| 150 | IXHL | Incannex Healthcare Inc. Australia · score 0.0 | 0% | 0.0 bn | 0.0 bn | — | -0.0 bn | -37.2% | — | Clinical-stage biopharma in serious chronic diseases · Australia | |
| 151 | NNVC | NANOVIRICIDES, INC. United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | — | -0.0 bn | -23.4% | — | Clinical-stage biotech with its first drug in phase II · Connecticut | |
| 152 | CPHI | CHINA PHARMA HOLDINGS, INC. China · score 0.6 | 0% | 0.0 bn | 0.0 bn | -114.3% | 0.0 bn | -0.7% | — | Pharmaceutical holding company in China · China — revenue of $4m | |
| 153 | IBO | IMPACT BIOMEDICAL INC. United States · score 1.6 | 0% | 0.0 bn | 0.0 bn | 23x | 0.0 bn | -1.9% | — | Discovery and patenting of biomedical science to license to health and wellness partners · Texas | |
| 154 | IGC | IGC Pharma, Inc. United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | -702.1% | -0.0 bn | -23.9% | — | Alzheimer's therapies using cannabinoids and AI · Maryland — revenue of $1m | |
| 155 | ABVC | ABVC BIOPHARMA, INC. United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | -890.6% | 0.0 bn | -11.1% | — | Seven licensed drugs and one medical device in development · California | |
| 156 | BYSI | BeyondSpring Inc. United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | — | -0.0 bn | -79.4% | — | Global clinical-stage biopharma in oncology · New Jersey | |
| 157 | NEUP | Neuphoria Therapeutics Inc. United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | -11x | -0.0 bn | -69.0% | — | Clinical-stage biotech in neuropsychiatric disorders · Massachusetts — revenue of $1m | |
| 158 | DARE | Dare Bioscience, Inc. United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | -804.3% | -0.0 bn | -84.6% | — | Biotech focused on women's health · California — revenue of $1m | |
| 159 | ALLR | Allarity Therapeutics, Inc. United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | -36x | -0.0 bn | -99.2% | — | Pharma in precision oncology medicine · Massachusetts | |
| 160 | HIND | Vyome Holdings, Inc United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | -87x | -0.0 bn | -43.2% | — | Next-generation antibiotics in partnership with Sun Pharma · California | |
| 161 | LPCN | Lipocine Inc. United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | -755.3% | -0.0 bn | -88.8% | — | Oral delivery of poorly absorbed molecules · United States — revenue of $2m | |
| 162 | ASBP | Aspire Biopharma Holdings, Inc. United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | -1842x | -0.0 bn | -60.9% | — | Sublingual delivery of known drugs and supplements, such as aspirin and caffeine, at an early stage · Florida | |
| 163 | KPRX | KIORA PHARMACEUTICALS INC United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | — | -0.0 bn | -82.0% | — | Clinical-stage pharma in retinal diseases · California | |
| 164 | BLRX | BioLineRx Ltd. Israel · score 0.0 | 0% | 0.0 bn | 0.0 bn | -728.4% | -0.0 bn | -109.4% | — | Therapies for oncology and rare diseases, from Israel · Israel — revenue of $1m | |
| 165 | ENSC | Ensysce Biosciences, Inc. United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | -280.5% | -0.0 bn | -91.6% | — | Clinical-stage pharma in pain relief with lower abuse risk · California — revenue of $5m | |
| 166 | VTGN | Vistagen Therapeutics, Inc. United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | -27x | -0.1 bn | -700.0% | — | Late-stage therapies for social anxiety, depression and hot flashes · California — revenue of $3m | |
| 167 | INM | InMed Pharmaceuticals Inc. Canada · score 0.0 | 0% | 0.0 bn | 0.0 bn | -278.7% | -0.0 bn | -115.3% | — | Development of molecules for cannabinoid receptors · Canada — revenue of $5m | |
| 168 | XCUR | EXICURE, INC. United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | — | -0.0 bn | -95.3% | — | Burixafor, a CXCR4 inhibitor for acute myeloid leukemia; exploring strategic alternatives · Illinois | |
| 169 | TRAW | Traws Pharma, Inc. United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | -773.0% | -0.0 bn | -340.9% | — | Clinical-stage biopharma in respiratory viral diseases · Pennsylvania — revenue of $3m | |
| 170 | CANF | Can-Fite BioPharma Ltd. Israel · score 0.0 | 0% | 0.0 bn | 0.0 bn | -24x | -0.0 bn | -166.9% | — | Oral molecules for cancer and liver diseases, from Israel · Israel | |
| 171 | ADXN | Addex Therapeutics Ltd. Switzerland · score 0.0 | 0% | 0.0 bn | 0.0 bn | -83x | 0.0 bn | -58.0% | — | Allosteric modulators for neurological diseases, from Switzerland · Switzerland | |
| 172 | SCNX | Scienture Holdings, Inc. United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | -46x | -0.0 bn | -300.9% | — | Cardiovascular and neurological specialty pharma · New York | |
| 173 | XTLB | XTL BIOPHARMACEUTICALS LTD Israel · score 0.4 | 0% | 0.0 bn | 0.0 bn | — | 0.0 bn | -23.5% | — | Psychedelic medicines (psilocybin, ibogaine) for mental and neurological disorders, in clinical development · Israel | |
| 174 | GELS | Gelteq Ltd Australia · score 0.0 | 0% | 0.0 bn | 0.0 bn | -43x | 0.0 bn | -83.9% | — | Oral gels for delivering medicines and supplements, from Australia · Australia | |
| 175 | RDHL | RedHill Biopharma Ltd. Israel · score 0.0 | 0% | 0.0 bn | 0.0 bn | — | -0.0 bn | -204.7% | — | Specialty biopharma for gastroenterology and oncology · Israel | |
| 176 | SXTP | 60 DEGREES PHARMACEUTICALS, INC. United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | -729.9% | -0.0 bn | -306.7% | — | Drugs for tropical and infectious diseases · Washington, DC — revenue of $1m | |
| 177 | PRFX | PRF Technologies Ltd. Israel · score 0.0 | 0% | 0.0 bn | 0.0 bn | -182x | 0.0 bn | -176.4% | — | Reformulation of established medicines · Israel | |
| 178 | NXTS | Nexentis Technologies Inc. United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | -77x | 0.0 bn | -493.7% | — | Solar projects and oncology biotech · New York | |
| 179 | CRIS | CURIS INC United States · score 0.0 | 0% | 0.0 bn | 0.0 bn | -490.3% | -0.0 bn | -38x | — | Biotech developing an IRAK4 and FLT3 inhibitor · Massachusetts — revenue of $4m | |
| 180 | LONA | LeonaBio, Inc. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.1 bn | -130.1% | — | Clinical-stage biopharma for breast cancer and ALS · Washington | |
| 181 | DWTX | Dogwood Therapeutics, Inc. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -36.8% | — | Pre-revenue biopharma in pain and neuropathy drugs · Georgia | |
| 182 | ALDX | Aldeyra Therapeutics, Inc. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -54.9% | — | Biotech in therapies for immune-mediated diseases · Massachusetts | |
| 183 | GRCE | Grace Therapeutics, Inc. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -26.0% | — | Rare disease drugs with novel routes of administration · New Jersey | |
| 184 | VERU | VERU INC. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -66.1% | — | Late clinical-stage biopharma in cardiometabolic diseases · Florida | |
| 185 | QNCX | Quince Therapeutics, Inc. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.1 bn | -134.3% | — | Biotech developing therapies for rare diseases · California | |
| 186 | FLNA | FILANA THERAPEUTICS, INC. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -89.3% | — | Development of drugs for nervous system disorders · Texas | |
| 187 | MIRA | MIRA PHARMACEUTICALS, INC. United States · score 0.0 | 0% | 0.0 bn | — | — | 0.0 bn | -17.2% | — | Oral drugs for neurological and metabolic diseases · Florida | |
| 188 | ATOS | ATOSSA THERAPEUTICS, INC. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -140.3% | — | Oncology drugs, focused on breast cancer · Washington | |
| 189 | SHPH | Shuttle Pharmaceuticals Holdings, Inc. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -29.3% | — | Radiosensitizers for cancer treatment · Maryland | |
| 190 | QNRX | Quoin Pharmaceuticals Ltd. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -80.0% | — | Late-stage pharma in rare and orphan diseases · Virginia | |
| 191 | COCP | Cocrystal Pharma, Inc. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -43.5% | — | Clinical-stage biotech in antivirals · Washington | |
| 192 | ACTU | ACTUATE THERAPEUTICS, INC. United States · score 1.2 | 0% | 0.0 bn | — | — | -0.0 bn | -137.7% | — | Elraglusib, a GSK-3β inhibitor for cancer · Texas | |
| 193 | KTTA | Pasithea Therapeutics Corp. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -128.9% | — | Clinical-stage biotech in RASopathies and MAPK pathway tumors · Florida | |
| 194 | REVB | REVELATION BIOSCIENCES, INC. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -71.2% | — | Clinical-stage life sciences in rebalancing inflammation · California | |
| 195 | TVRD | Tvardi Therapeutics, Inc. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -194.0% | — | Clinical-stage biopharma in oral STAT3 inhibitors · Texas | |
| 196 | INTS | INTENSITY THERAPEUTICS, INC. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -83.7% | — | Late-stage biotech in localized tumor reduction · Connecticut | |
| 197 | CLRB | Cellectar Biosciences, Inc. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -183.8% | — | Late-stage biopharma in cancer treatments · New Jersey | |
| 198 | TPST | Tempest Therapeutics, Inc. United States · score 0.2 | 0% | 0.0 bn | — | — | -0.0 bn | -205.2% | — | Clinical-stage biotech in cell therapy and small molecules · California | |
| 199 | ADIL | ADIAL PHARMACEUTICALS, INC. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -117.2% | — | Clinical-stage biopharma of addiction treatments · Virginia | |
| 200 | MTVA | MetaVia Inc. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -195.5% | — | Clinical-stage biotech in cardiometabolic diseases · Massachusetts | |
| 201 | CURX | Curanex Pharmaceuticals Inc United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -156.9% | — | Plant-derived oral medicine for respiratory diseases · New York | |
| 202 | SNGX | SOLIGENIX, INC. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -131.7% | — | Specialty biotech and public health solutions · New Jersey | |
| 203 | CNSP | CNS Pharmaceuticals, Inc. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -184.1% | — | Biotech in neurology and oncology therapies · Texas | |
| 204 | CALC | CalciMedica, Inc. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -273.1% | — | Clinical-stage biopharma in inflammatory and immune diseases · California | |
| 205 | APRE | Aprea Therapeutics, Inc. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -181.6% | — | Clinical-stage precision oncology for biomarker-defined cancers · Pennsylvania | |
| 206 | ALZN | Alzamend Neuro, Inc. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -106.9% | — | Drugs for Alzheimer's and bipolar disorder · Georgia | |
| 207 | ENVB | Enveric Biosciences, Inc. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -138.1% | — | Biotech of neuroplastogens for psychiatric disorders · Massachusetts | |
| 208 | ACXP | Acurx Pharmaceuticals, Inc. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -103.0% | — | Late-stage biopharma in antibiotics for hard-to-treat infections · New York | |
| 209 | PULM | Pulmatrix, Inc. United States · score 0.0 | 0% | 0.0 bn | — | — | 0.0 bn | -75.2% | — | Biopharma in inhaled therapies for migraine and respiratory disease · Massachusetts | |
| 210 | PCSA | Processa Pharmaceuticals, Inc. United States · score 0.2 | 0% | 0.0 bn | — | — | -0.0 bn | -249.4% | — | Clinical-stage biopharma · Florida | |
| 211 | NCNA | NuCana plc United Kingdom · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -166.6% | — | ProTide chemotherapy drugs (modified nucleoside analogs) for cancer, in clinical development · United Kingdom | |
| 212 | CVKD | Cadrenal Therapeutics, Inc. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -267.6% | — | Late-stage biopharma in immune and thrombotic diseases · Florida | |
| 213 | GRI | GRI Bio, Inc. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -325.6% | — | Clinical-stage biopharma in inflammatory and autoimmune diseases · California | |
| 214 | EOCN | Galmed Pharmaceuticals Ltd. Israel · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -284.8% | — | Medicines for liver diseases, from Israel · Israel | |
| 215 | OGEN | ORAGENICS INC United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -537.2% | — | Nasally administered medicines for neurological diseases · Florida | |
| 216 | MTNB | Matinas BioPharma Holdings, Inc. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -401.3% | — | Clinical-stage biopharma of lipid nanocrystals · New Jersey | |
| 217 | ARTL | ARTELO BIOSCIENCES, INC. United States · score 0.0 | 0% | 0.0 bn | — | — | -0.0 bn | -902.4% | — | Clinical-stage biopharma in the endocannabinoid system · California | |
| 218 | LABT | Lakewood-Amedex Biotherapeutics Inc. United States · score 0.0 | 0% | 0.0 bn | — | — | 0.0 bn | -249.0% | — | Biotech for infectious diseases · Florida | |
| 219 | BGM | BGM Group Ltd. China · score 1.5 | — | — | 0.0 bn | -52.6% | 0.0 bn | — | — | Pharmaceutical holding company operating in China · China — revenue of $38m | |
| 220 | JAGX | Jaguar Health, Inc. United States · score 0.3 | — | — | 0.0 bn | -192.6% | -0.0 bn | — | — | Plant-derived drugs for gastrointestinal diseases · California — revenue of $28m | |
| 221 | APLM | Apollomics Inc. United States · score 0.0 | — | — | 0.0 bn | -128.7% | -0.0 bn | — | — | Cancer drugs, including a c-Met inhibitor for lung cancer, in clinical stage · California — revenue of $8m | |
| 222 | RADX | Radiopharm Theranostics Ltd Australia · score 0.3 | — | — | 0.0 bn | -21x | -0.1 bn | — | — | Radiopharmaceuticals for diagnosis and therapy, from Australia · Australia — revenue of $3m | |
| 223 | SXTC | China SXT Pharmaceuticals, Inc. China · score 1.1 | — | — | 0.0 bn | -545.3% | 0.0 bn | — | — | Traditional Chinese medicine in tablets and powder · China — revenue of $1m | |
| 224 | SPRC | SciSparc Ltd. Israel · score 0.8 | — | — | 0.0 bn | -14x | -0.0 bn | — | — | Medicines for central nervous system disorders, from Israel · Israel | |
| 225 | LEXX | Lexaria Bioscience Corp. Canada · score 0.4 | — | — | 0.0 bn | -40x | -0.0 bn | — | — | Bioavailability biotech with DehydraTECH technology · Canada | |
| 226 | LSTA | LISATA THERAPEUTICS, INC. United States · score 0.4 | — | — | 0.0 bn | -146x | -0.0 bn | — | — | Clinical-stage pharma in solid tumors · New Jersey | |
| 227 | SILO | Silo Pharma, Inc. United States · score 0.6 | — | — | 0.0 bn | -83x | 0.0 bn | — | — | Biopharma in development and digital assets · Florida | |
| 228 | KZIA | KAZIA THERAPEUTICS LTD Australia · score 0.8 | — | — | 0.0 bn | -549x | -0.0 bn | — | — | Clinical-stage oncology, from Australia · Australia | |
| 229 | JUNS | JUPITER NEUROSCIENCES, INC. United States · score 0.0 | — | — | 0.0 bn | -418x | -0.0 bn | — | — | Clinical-stage neuroinflammation research on a resveratrol platform · Florida | |
| 230 | TCRT | Alaunos Therapeutics, Inc. United States · score 0.4 | — | — | 0.0 bn | -1337x | 0.0 bn | — | — | Preclinical biopharma in obesity and metabolic disorders · Florida | |
| 231 | EPRX | EUPRAXIA PHARMACEUTICALS INC. Canada · score 1.2 | — | — | 0.0 bn | — | -0.0 bn | — | — | Long-acting injectable medicines, from Canada · Canada | |
| 232 | NTHI | NEONC TECHNOLOGIES HOLDINGS, INC. United States · score 2.3 | — | — | 0.0 bn | — | -0.0 bn | — | — | Drug delivery to the brain for brain tumors · California | |
| 233 | MPLT | MapLight Therapeutics, Inc. United States · score 1.2 | — | — | — | — | -0.2 bn | — | — | Drugs for central nervous system disorders · California | |
| 234 | CDT | CDT Equity Inc. United States · score 1.0 | — | — | — | — | -0.0 bn | — | — | Data-driven pharmaceutical development and digital asset treasury · Florida | |
| 235 | UPC | Universe Pharmaceuticals INC China · score 3.0 | — | — | — | — | -5.3 bn | — | — | Traditional Chinese medicine in tablets and capsules · China | |
| 236 | MSLE | Satellos Bioscience Inc. Canada · score 1.3 | — | — | — | — | -0.0 bn | — | — | Therapies for muscle regeneration, from Canada · Canada | |
| 237 | MDCX | Medicus Pharma Ltd. United States · score 0.3 | — | — | — | — | -0.0 bn | — | — | Topical therapy for basal cell carcinoma · Pennsylvania | |
| 238 | PPBT | PURPLE BIOTECH LTD. Israel · score 1.0 | — | — | — | — | -0.0 bn | — | — | Clinical-stage oncology drugs, from Israel · Israel | |
| 239 | PBM | PSYENCE BIOMEDICAL LTD. Canada · score 1.4 | — | — | — | — | -0.0 bn | — | — | Natural psychedelics for mental health · Canada | |
| 240 | BDRX | Biodexa Pharmaceuticals Plc United Kingdom · score 1.2 | — | — | — | — | -0.0 bn | — | — | Drugs for familial adenomatous polyposis, gastrointestinal cancer and type 1 diabetes, in clinical development · United Kingdom | |
| 241 | CMND | Clearmind Medicine Inc. Canada · score 1.0 | — | — | — | — | -0.0 bn | — | — | Non-hallucinogenic psychedelic derivatives for alcohol use disorder and mental and metabolic disorders, in clinical development · Canada | |
| 242 | CRDL | Cardiol Therapeutics Inc. Canada · score 0.8 | — | — | — | — | -0.0 bn | — | — | Clinical-stage cardiovascular therapies, from Canada · Canada | |
| 243 | NGEN | NERVGEN PHARMA CORP. Canada · score 1.2 | — | — | — | — | -0.0 bn | — | — | Therapies for spinal cord injury, from Canada · Canada | |
| 244 | PYPD | PolyPid Ltd. Israel · score 0.5 | — | — | — | — | -0.0 bn | — | — | Localized post-surgical drug delivery, from Israel · Israel | |
| 245 | QNTM | Quantum Biopharma Ltd. Canada · score 3.6 | — | — | — | — | -0.0 bn | — | — | Licensed medicines for multiple sclerosis · Canada | |
| 246 | BIVI | BIOVIE INC. United States · score 0.8 | — | — | — | — | -0.0 bn | — | — | Clinical-stage therapies for neurological disorders and liver disease · Nevada | |
| 247 | NSRX | Nasus Pharma Ltd Israel · score 0.9 | — | — | — | — | -0.0 bn | — | — | Intranasal medicines for medical emergencies · Israel | |
| 248 | DCOY | Decoy Therapeutics Inc. United States · score 0.8 | — | — | — | — | -0.0 bn | — | — | Preclinical biotech of peptide conjugates · Texas | |
| 249 | DRMA | Dermata Therapeutics, Inc. United States · score 0.8 | — | — | — | — | -0.0 bn | — | — | Commercial dermatology for underserved skin conditions · California | |
| 250 | XRTX | XORTX Therapeutics Inc. Canada · score 0.9 | — | — | — | — | 0.0 bn | — | — | Therapies for kidney diseases, from Canada · Canada | |
| 251 | NRSN | NeuroSense Therapeutics Ltd. Israel · score 1.9 | — | — | — | — | -0.0 bn | — | — | PrimeC drug for amyotrophic lateral sclerosis, from Israel · Israel |
Other industries in the same sector
- Sector overview
- Large-cap pharmaceuticals 9 companies
- Biotechnology 57 companies
- European pharmaceuticals 5 companies
- Lab tools and consumables 37 companies
- Health insurance and services 17 companies
- Medical devices 87 companies
- Specialty pharmaceuticals 77 companies
- Pharmaceutical distribution 7 companies
- Robotic surgery and advanced medtech 9 companies
- Hospitals 23 companies
- Emerging biotech 5 companies
- Molecular testing and advanced diagnostics 42 companies
and 22 industries more
- Vaccines and mRNA 14 companies
- Clinical-stage biotech 200 companies
- Generics and biosimilars 10 companies
- Animal health 7 companies
- Contract research (CRO) 10 companies
- Consumer health (OTC) 4 companies
- Healthcare software 18 companies
- Rehabilitation and home care 15 companies
- Genomics and sequencing 9 companies
- Structural heart 8 companies
- Ophthalmology 12 companies
- Medical imaging and hospital equipment 16 companies
- Diagnostic labs 6 companies
- Medical and dental supply distribution 3 companies
- Diabetes monitoring 9 companies
- Pharmaceutical royalties 5 companies
- Respiratory and sleep therapy 9 companies
- Orthopedic implants 17 companies
- Dialysis 3 companies
- Telehealth and digital health 12 companies
- Dental 4 companies
- Medical and recreational cannabis 16 companies
What this is. A catalogue, not a guide. Every industry with stocks listed on the NYSE or NASDAQ, the companies contending for its leadership, what each one does according to its own annual report, and the balance sheet it filed with the SEC.
The score runs from 0 to 10 and compares each company with every other one in the almanac on cash generation, profitability, debt, dividends and consistency over the last five years. The higher it is, the better the company fares in that comparison. Curious how much each part weighs? Ask at the bottom of the page.
The score runs from 0 to 10 and compares each company with every other one in the almanac on cash generation, profitability, debt, dividends and consistency over the last five years. The higher it is, the better the company fares in that comparison. Curious how much each part weighs? Ask at the bottom of the page.